
### [MONDO:0004126](http://purl.obolibrary.org/obo/MONDO_0004126)
**Label:** thyroiditis (disease)

**Subclasses:** [MONDO:0011981](http://purl.obolibrary.org/obo/MONDO_0011981) (autoimmune thyroid disease, susceptibility to, 2), [MONDO:0001948](http://purl.obolibrary.org/obo/MONDO_0001948) (Riedel's fibrosing thyroiditis), [MONDO:0011980](http://purl.obolibrary.org/obo/MONDO_0011980) (autoimmune thyroid disease, susceptibility to, 1), [MONDO:0001947](http://purl.obolibrary.org/obo/MONDO_0001947) (suppurative thyroiditis), [MONDO:0001949](http://purl.obolibrary.org/obo/MONDO_0001949) (acute thyroiditis), [MONDO:0001555](http://purl.obolibrary.org/obo/MONDO_0001555) (neonatal thyrotoxicosis), [MONDO:0005624](http://purl.obolibrary.org/obo/MONDO_0005624) (atrophic thyroiditis), [MONDO:0005623](http://purl.obolibrary.org/obo/MONDO_0005623) (autoimmune thyroid disease), [MONDO:0004135](http://purl.obolibrary.org/obo/MONDO_0004135) (subacute lymphocytic thyroiditis), [MONDO:0007699](http://purl.obolibrary.org/obo/MONDO_0007699) (Hashimoto thyroiditis), [MONDO:0006982](http://purl.obolibrary.org/obo/MONDO_0006982) (subacute thyroiditis), [MONDO:0000162](http://purl.obolibrary.org/obo/MONDO_0000162) (autoimmune thyroid disease, susceptibility to), [MONDO:0005364](http://purl.obolibrary.org/obo/MONDO_0005364) (Graves disease), [MONDO:0011314](http://purl.obolibrary.org/obo/MONDO_0011314) (Graves disease, susceptibility to, 2), [MONDO:0011983](http://purl.obolibrary.org/obo/MONDO_0011983) (autoimmune thyroid disease, susceptibility to, 4), [MONDO:0011982](http://purl.obolibrary.org/obo/MONDO_0011982) (autoimmune thyroid disease, susceptibility to, 3), [MONDO:0010138](http://purl.obolibrary.org/obo/MONDO_0010138) (thyrotoxicosis), [MONDO:0010304](http://purl.obolibrary.org/obo/MONDO_0010304) (Graves disease, susceptibility to, X-linked 1), 

**Mapped go classes:** [GO:0009897](http://purl.obolibrary.org/obo/GO_0009897) (external side of plasma membrane), [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus), [GO:0043168](http://purl.obolibrary.org/obo/GO_0043168) (anion binding), [GO:0005576](http://purl.obolibrary.org/obo/GO_0005576) (extracellular region), [GO:0005179](http://purl.obolibrary.org/obo/GO_0005179) (hormone activity), [GO:0005887](http://purl.obolibrary.org/obo/GO_0005887) (integral component of plasma membrane), [GO:0045590](http://purl.obolibrary.org/obo/GO_0045590) (negative regulation of regulatory T cell differentiation), [GO:0030889](http://purl.obolibrary.org/obo/GO_0030889) (negative regulation of B cell proliferation), [GO:0006955](http://purl.obolibrary.org/obo/GO_0006955) (immune response), [GO:0045056](http://purl.obolibrary.org/obo/GO_0045056) (transcytosis), [GO:0051087](http://purl.obolibrary.org/obo/GO_0051087) (chaperone binding), [GO:0015705](http://purl.obolibrary.org/obo/GO_0015705) (iodide transport), [GO:0098636](http://purl.obolibrary.org/obo/GO_0098636) (protein complex involved in cell adhesion), [GO:0050777](http://purl.obolibrary.org/obo/GO_0050777) (negative regulation of immune response), [GO:0032403](http://purl.obolibrary.org/obo/GO_0032403) (protein complex binding), [GO:0050853](http://purl.obolibrary.org/obo/GO_0050853) (B cell receptor signaling pathway), [GO:0042803](http://purl.obolibrary.org/obo/GO_0042803) (protein homodimerization activity), [GO:0006590](http://purl.obolibrary.org/obo/GO_0006590) (thyroid hormone generation), [GO:0002250](http://purl.obolibrary.org/obo/GO_0002250) (adaptive immune response), [GO:0009268](http://purl.obolibrary.org/obo/GO_0009268) (response to pH), [GO:0005783](http://purl.obolibrary.org/obo/GO_0005783) (endoplasmic reticulum), [GO:0045334](http://purl.obolibrary.org/obo/GO_0045334) (clathrin-coated endocytic vesicle), [GO:0043234](http://purl.obolibrary.org/obo/GO_0043234) (protein complex), [GO:0006974](http://purl.obolibrary.org/obo/GO_0006974) (cellular response to DNA damage stimulus), [GO:0005102](http://purl.obolibrary.org/obo/GO_0005102) (receptor binding), [GO:0002376](http://purl.obolibrary.org/obo/GO_0002376) (immune system process), [GO:0005886](http://purl.obolibrary.org/obo/GO_0005886) (plasma membrane), [GO:0042446](http://purl.obolibrary.org/obo/GO_0042446) (hormone biosynthetic process), [GO:0042403](http://purl.obolibrary.org/obo/GO_0042403) (thyroid hormone metabolic process), [GO:0003676](http://purl.obolibrary.org/obo/GO_0003676) (nucleic acid binding), [GO:0005615](http://purl.obolibrary.org/obo/GO_0005615) (extracellular space), [GO:0048471](http://purl.obolibrary.org/obo/GO_0048471) (perinuclear region of cytoplasm), [GO:0046872](http://purl.obolibrary.org/obo/GO_0046872) (metal ion binding), [GO:0042130](http://purl.obolibrary.org/obo/GO_0042130) (negative regulation of T cell proliferation), [GO:0043065](http://purl.obolibrary.org/obo/GO_0043065) (positive regulation of apoptotic process), [GO:0016020](http://purl.obolibrary.org/obo/GO_0016020) (membrane), [GO:0016021](http://purl.obolibrary.org/obo/GO_0016021) (integral component of membrane), [GO:0031641](http://purl.obolibrary.org/obo/GO_0031641) (regulation of myelination), 

**Class expressions from DL-Learner:**

- [GO:0051087](http://purl.obolibrary.org/obo/GO_0051087) (chaperone binding) 58.33%
- [GO:0042803](http://purl.obolibrary.org/obo/GO_0042803) (protein homodimerization activity) 58.33%
- [GO:0042802](http://purl.obolibrary.org/obo/GO_0042802) (identical protein binding) 58.33%
- [GO:0042403](http://purl.obolibrary.org/obo/GO_0042403) (thyroid hormone metabolic process) 58.33%
- [GO:0030889](http://purl.obolibrary.org/obo/GO_0030889) (negative regulation of B cell proliferation) 58.33%
- [GO:0006590](http://purl.obolibrary.org/obo/GO_0006590) (thyroid hormone generation) 58.33%
- [GO:0005794](http://purl.obolibrary.org/obo/GO_0005794) (Golgi apparatus) 58.33%
- [GO:0005615](http://purl.obolibrary.org/obo/GO_0005615) (extracellular space) 58.33%
- [GO:0050869](http://purl.obolibrary.org/obo/GO_0050869) (negative regulation of B cell activation) and [GO:0070664](http://purl.obolibrary.org/obo/GO_0070664) (negative regulation of leukocyte proliferation) 58.33%
- [GO:0050869](http://purl.obolibrary.org/obo/GO_0050869) (negative regulation of B cell activation) and [GO:0070663](http://purl.obolibrary.org/obo/GO_0070663) (regulation of leukocyte proliferation) 58.33%
- [GO:0050864](http://purl.obolibrary.org/obo/GO_0050864) (regulation of B cell activation) and [GO:0070664](http://purl.obolibrary.org/obo/GO_0070664) (negative regulation of leukocyte proliferation) 58.33%
- [GO:0050672](http://purl.obolibrary.org/obo/GO_0050672) (negative regulation of lymphocyte proliferation) and [GO:0050869](http://purl.obolibrary.org/obo/GO_0050869) (negative regulation of B cell activation) 58.33%
- [GO:0050672](http://purl.obolibrary.org/obo/GO_0050672) (negative regulation of lymphocyte proliferation) and [GO:0050864](http://purl.obolibrary.org/obo/GO_0050864) (regulation of B cell activation) 58.33%
- [GO:0050670](http://purl.obolibrary.org/obo/GO_0050670) (regulation of lymphocyte proliferation) and [GO:0050869](http://purl.obolibrary.org/obo/GO_0050869) (negative regulation of B cell activation) 58.33%
- [GO:0042802](http://purl.obolibrary.org/obo/GO_0042802) (identical protein binding) and [GO:0046983](http://purl.obolibrary.org/obo/GO_0046983) (protein dimerization activity) 58.33%


